Back to Search
Start Over
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
- Source :
- Journal of Experimental & Clinical Cancer Research : CR, Journal of experimental & clinical cancer research 40(1), 288 (2021). doi:10.1186/s13046-021-02043-0, Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-14 (2021)
- Publication Year :
- 2021
- Publisher :
- BioMed Central, 2021.
-
Abstract
- Journal of experimental & clinical cancer research 40(1), 288 (2021). doi:10.1186/s13046-021-02043-0<br />Published by Springer, Berlin ; Heidelberg
- Subjects :
- Cancer Research
Combination therapy
Colorectal cancer
Pyridines
medicine.medical_treatment
Programmed Cell Death 1 Receptor
Macrophage polarization
Metastasis
chemistry.chemical_compound
Mice
Regorafenib
Cell Line, Tumor
Medicine
Animals
Humans
RC254-282
Tumor microenvironment
business.industry
Research
Phenylurea Compounds
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Drug Synergism
Immunotherapy
medicine.disease
Preclinical
Oncology
chemistry
Apoptosis
Cancer research
Anti-PD1 antibody
business
Colorectal Neoplasms
Subjects
Details
- Language :
- English
- ISSN :
- 17569966 and 03929078
- Volume :
- 40
- Database :
- OpenAIRE
- Journal :
- Journal of Experimental & Clinical Cancer Research : CR
- Accession number :
- edsair.doi.dedup.....ab98cf9179bb969a3e3b7319e8b77865
- Full Text :
- https://doi.org/10.1186/s13046-021-02043-0